May 27, 2022 - 11am
MaRS Discovery District, Toronto
A.I./M.L. innovations now affect almost every aspect of our lives. As the digital merges with the biological, many new opportunities will emerge in our ability to discover, deploy and market new therapeutics.
Meet several A.I.-based ventures — Cyclica, BenchSci, ODAIA and deepCDR — changing our perspectives on pharmaceuticals as they move from bench to bedside.
Vivek Goel, President and Vice-Chancellor, University of Waterloo
Helen Kontozopoulos, Co-founder, Chief Tech Evangelist, ODAIA.ai
John Chan, Head, Takeda ShinrAI Center for Artificial Intelligence and Machine Learning
Sai Reddy, Founder, deepCDR Biologics
Stephen MacKinnon, Chief Platform Officer, Cyclica
Tom Leung, MSc PhD, Founder and CSO, BenchSci
By Helen Kontozopoulos, Co-founder & Tech Evangelist, ODAIA.ai
Co-Founder and Chief Tech Evangelist at ODAIA.ai